{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:04:16Z","timestamp":1793678656767,"version":"4.5.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":90,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.semnephrol.2023.151435","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T12:42:45Z","timestamp":1699447365000},"page":"151435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Glomerular Diseases Across Lifespan: Key Differences in Diagnostic and Therapeutic Approaches"],"prefix":"10.1016","volume":"43","author":[{"given":"Martin","family":"Windpessl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Odler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg M.","family":"Bajema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0001","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/j.ackd.2017.09.005","article-title":"Glomerular diseases in children","volume":"24","author":"Wenderfer","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0002","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey","volume":"33","author":"O'Shaughnessy","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0003","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2215\/CJN.00980207","article-title":"Kidney disease screening program in Japan: history, outcome, and perspectives","volume":"2","author":"Imai","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151435_bib0004","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00467-020-04773-3","article-title":"Adult survivors of idiopathic childhood onset nephrotic syndrome","volume":"36","author":"Marchel","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0005","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1681\/ASN.2017121260","article-title":"The prognostic value of histopathologic lesions in native kidney biopsy specimens: results from the Boston Kidney Biopsy Cohort Study","volume":"29","author":"Srivastava","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0006","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11255-022-03371-6","article-title":"Modified histopathological classification with age-related glomerulosclerosis for predicting kidney survival in ANCA-associated glomerulonephritis","volume":"55","author":"Ayd\u0131n","year":"2023","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0007","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2017.09.028","article-title":"Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment","volume":"93","author":"Hommos","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0008","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria","volume":"69","author":"Ozen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10141","key":"10.1016\/j.semnephrol.2023.151435_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","article-title":"Idiopathic nephrotic syndrome in children","volume":"392","author":"Noone","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00467-022-05520-6","article-title":"Therapeutic trials in difficult to treat steroid sensitive nephrotic syndrome: challenges and future directions","volume":"38","author":"McKay","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0011","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome","volume":"38","author":"Trautmann","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0012","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jmedgenet-2017-104811","article-title":"Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations","volume":"54","author":"Sen","year":"2017","journal-title":"J Med Genet"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0013","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40620-023-01631-x","article-title":"Predictors of long-term outcomes in pediatric focal segmental glomerulosclerosis","volume":"36","author":"Peng","year":"2023","journal-title":"J Nephrol"},{"issue":"suppl 6)","key":"10.1016\/j.semnephrol.2023.151435_bib0014","first-page":"vi52","article-title":"Secondary minimal change disease","volume":"18(","author":"Glassock","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0015","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.2215\/CJN.06620615","article-title":"AKI in children hospitalized with nephrotic syndrome","volume":"10","author":"Rheault","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0016","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.kint.2018.04.024","article-title":"Acute kidney injury complicating nephrotic syndrome of minimal change disease","volume":"94","author":"Meyrier","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0017","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.ajkd.2016.10.032","article-title":"The clinical course of minimal change nephrotic syndrome with onset in adulthood or late adolescence: a case series","volume":"69","author":"Maas","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"9950","key":"10.1016\/j.semnephrol.2023.151435_bib0018","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00467-021-04983-3","article-title":"Update on the treatment of steroid-sensitive nephrotic syndrome","volume":"37","author":"Zotta","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":"Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome","volume":"24","author":"Gellermann","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2021050643","article-title":"Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome","volume":"33","author":"Iijima","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0022","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.kint.2018.07.021","article-title":"An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study)","volume":"94","author":"R\u00e9my","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00467-021-04985-1","article-title":"Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome","volume":"37","author":"Christian","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0024","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00467-021-05175-9","article-title":"Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study","volume":"37","author":"Vivarelli","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"4S","key":"10.1016\/j.semnephrol.2023.151435_bib0025","first-page":"S1","article-title":"KDIGO 2021 Clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.semnephrol.2023.151435_bib0026","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMc1308488","article-title":"Ofatumumab for rituximab-resistant nephrotic syndrome","volume":"370","author":"Basu","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0027","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1681\/ASN.2021040561","article-title":"Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial","volume":"32","author":"Ravani","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0028","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00467-020-04811-0","article-title":"A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome","volume":"36","author":"Dossier","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000495351","article-title":"Shortening the duration of corticosteroid exposure in minimal change disease: can we treat adults like children?","volume":"49","author":"Bomback","year":"2019","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000495352","article-title":"Short-term steroid regimen for adult steroid-sensitive minimal change disease","volume":"49","author":"Ozeki","year":"2019","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0031","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2022.04.007","article-title":"A clinical response-adjusted steroid treatment protocol for children with newly diagnosed idiopathic nephrotic syndrome","volume":"80","author":"Zion","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0032","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0033","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0034","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","article-title":"Podocytopathies","volume":"6","author":"Kopp","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41581-020-00384-1","article-title":"Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group","volume":"17","author":"Boyer","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0036","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/gfv325","article-title":"Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis","volume":"31","author":"Gast","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151435_bib0037","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0038","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ekir.2022.10.004","article-title":"Novel treatment paradigms: focal segmental glomerulosclerosis","volume":"8","author":"de Cos","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0039","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"10.1016\/j.semnephrol.2023.151435_bib0040","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0042","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0043","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1681\/ASN.2020081181","article-title":"Patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes","volume":"32","author":"Ravindran","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0044","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151435_bib0045","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMoa1013792","article-title":"Early-childhood membranous nephropathy due to cationic bovine serum albumin","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0046","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0047","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ekir.2019.09.005","article-title":"Treatment patterns among adults and children with membranous nephropathy in the Cure Glomerulonephropathy Network (CureGN)","volume":"4","author":"O'Shaughnessy","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0048","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s10067-019-04631-0","article-title":"Disease presentation of 1312 childhood-onset systemic lupus erythematosus: influence of ethnicity","volume":"38","author":"Fiorot","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0049","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/0961203314563817","article-title":"Similarities and differences between pediatric and adult patients with systemic lupus erythematosus","volume":"24","author":"Tarr","year":"2015","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0050","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/art.34472","article-title":"Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population","volume":"64","author":"Hiraki","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0051","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semnephrol.2023.151435_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.12.004","article-title":"A meta-analysis of clinical manifestations in Asian systemic lupus erythematous: the effects of ancestry, ethnicity and gender","volume":"52","author":"Lee","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151435_bib0053","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/0961203312443421","article-title":"Lupus nephritis is more severe in children and adolescents than in older adults","volume":"21","author":"Sato","year":"2012","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0054","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ekir.2022.10.014","article-title":"Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis","volume":"8","author":"Chan","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2013.07.005","article-title":"Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions","volume":"43","author":"Wu","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0056","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0057","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00467-021-05164-y","article-title":"Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis","volume":"37","author":"Qiu","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0058","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0059","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semnephrol.2023.151435_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102495","article-title":"Clinical associations of renal involvement in ANCA-associated vasculitis","author":"Kronbichler","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0061","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/art.39729","article-title":"Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener's): an ARChiVe cohort study","volume":"68","author":"Cabral","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151435_bib0062","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2215\/CJN.19181220","article-title":"Prognostic factors and long-term outcome with ANCA-associated kidney vasculitis in childhood","volume":"16","author":"Calatroni","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1)","key":"10.1016\/j.semnephrol.2023.151435_bib0063","first-page":"i104","article-title":"Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study","volume":"30(","author":"Sacri","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0064","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/acr.21565","article-title":"Airway manifestations in childhood granulomatosis with polyangiitis (Wegener's)","volume":"64","author":"Fowler","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0065","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/rheumatology\/keac423","article-title":"Classification criteria for ANCA-associated vasculitis: one size does not fit all!","volume":"62","author":"Kronbichler","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0066","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0067","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2012-202111","article-title":"Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)","volume":"72","author":"Dolezalova","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0068","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2215\/CJN.14561119","article-title":"Developments in the histopathological classification of ANCA-associated glomerulonephritis","volume":"15","author":"van Daalen","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151435_bib0069","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0070","doi-asserted-by":"crossref","first-page":"00017","DOI":"10.1183\/23120541.00017-2018","article-title":"Analysis of pulmonary features and treatment approaches in the COPA syndrome","volume":"4","author":"Tsui","year":"2018","journal-title":"ERJ Open Res"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0071","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00467-021-05333-z","article-title":"Anti-glomerular basement membrane disease in children: a brief overview","volume":"37","author":"Dowsett","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0072","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s10067-012-2062-9","article-title":"Characteristics and outcome of Goodpasture's disease in children","volume":"31","author":"Bayat","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0073","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/pr.2017.315","article-title":"Management and outcomes of childhood Goodpasture's disease","volume":"83","author":"Menzi","year":"2018","journal-title":"Pediatr Res"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151435_bib0074","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ndt\/gfy327","article-title":"Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies","volume":"34","author":"Segelmark","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151435_bib0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2369-12-21","article-title":"The association of HLA-DQB1, -DQA1 and -DPB1 alleles with anti- glomerular basement membrane (GBM) disease in Chinese patients","volume":"12","author":"Luo","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151435_bib0076","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaut.2014.01.024","article-title":"Diagnosis and classification of Goodpasture's disease (anti-GBM)","volume":"48-49","author":"Hellmark","year":"2014","journal-title":"J Autoimmun"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0077","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2215\/CJN.13591215","article-title":"Spatial and temporal clustering of anti-glomerular basement membrane disease","volume":"11","author":"Canney","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0078","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.kint.2020.06.009","article-title":"Anti-glomerular basement membrane disease during the COVID-19 pandemic","volume":"98","author":"Prendecki","year":"2020","journal-title":"Kidney Int"},{"issue":"8364","key":"10.1016\/j.semnephrol.2023.151435_bib0079","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(83)90923-6","article-title":"Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane","volume":"2","author":"Donaghy","year":"1983","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151435_bib0080","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.01380217","article-title":"Anti-glomerular basement membrane disease","volume":"12","author":"McAdoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151435_bib0081","article-title":"Antiglomerular basement membrane disease in a pediatric patient: a case report and review of the literature","volume":"2017","author":"Master Sankar Raj","year":"2017","journal-title":"Case Rep Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0082","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00467-010-1663-2","article-title":"A 25-year experience with pediatric anti-glomerular basement membrane disease","volume":"26","author":"Williamson","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0083","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ndt\/gfu399","article-title":"Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort","volume":"30","author":"Alchi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151435_bib0084","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2215\/CJN.04290417","article-title":"Predicting outcome in patients with anti-GBM glomerulonephritis","volume":"13","author":"van Daalen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0086","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.kint.2016.02.001","article-title":"The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis","volume":"89","author":"Nasr","year":"2016","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0087","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151435_bib0088","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2015.04.003","article-title":"Rituximab in anti-GBM disease: a retrospective study of 8 patients","volume":"60","author":"Touzot","year":"2015","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0089","doi-asserted-by":"crossref","first-page":"e14179","DOI":"10.1111\/ctr.14179","article-title":"Long-term outcomes in kidney transplant recipients with end-stage kidney disease due to anti-glomerular basement membrane disease","volume":"35","author":"Singh","year":"2021","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0090","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0091","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00467-021-04950-y","article-title":"IgA vasculitis with nephritis: update of pathogenesis with clinical implications","volume":"37","author":"Hastings","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0092","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0093","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/nep.13987","article-title":"Immunoglobulin A nephropathy in paediatrics: an up-to-date","volume":"27","author":"Paranhos","year":"2022","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0094","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.kint.2020.10.033","article-title":"Updating the international IgA nephropathy prediction tool for use in children","volume":"99","author":"Barbour","year":"2021","journal-title":"Kidney Int"},{"issue":"10388","key":"10.1016\/j.semnephrol.2023.151435_bib0095","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0096","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0098","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/ard-2022-222495","article-title":"Novel aspects in the pathophysiology and diagnosis of glomerular diseases","volume":"82","author":"Kronbichler","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151435_bib0099","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0100","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/art.1780330809","article-title":"The American College of Rheumatology 1990 criteria for the classification of Henoch-Sch\u00f6nlein purpura","volume":"33","author":"Mills","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0101","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/ckj\/sfaa251","article-title":"IgA vasculitis (Henoch-Sch\u00f6nlein purpura): refractory and relapsing disease course in the adult population","volume":"14","author":"Van de Perre","year":"2021","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0102","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00467-022-05706-y","article-title":"Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up","volume":"38","author":"Gjerstad","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0103","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0104","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00467-013-2550-4","article-title":"Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Sch\u00f6nlein purpura nephritis","volume":"28","author":"Davin","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151435_bib0105","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s00467-019-04327-2","article-title":"Does MEST-C score predict outcomes in pediatric Henoch-Sch\u00f6nlein purpura nephritis?","volume":"34","author":"Jimenez","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0106","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.ASN.0000013883.99976.22","article-title":"Henoch-Sch\u00f6nlein purpura in adults: outcome and prognostic factors","volume":"13","author":"Pillebout","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151435_bib0107","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-021-01013-x","article-title":"IgA vasculitis in adults: a rare yet challenging disease","volume":"23","author":"Yaseen","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0108","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ekir.2018.07.021","article-title":"Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0109","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","article-title":"Current treatment of IgA nephropathy","volume":"43","author":"Floege","year":"2021","journal-title":"Semin Immunopathol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ki.2010.150","article-title":"Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein purpura","volume":"78","author":"Pillebout","year":"2010","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0111","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00467-007-0498-y","article-title":"Treating severe Henoch-Sch\u00f6nlein and IgA nephritis with plasmapheresis alone","volume":"22","author":"Shenoy","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151435_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100534","article-title":"Mycophenolate mofetil for severe IgA vasculitis nephropathy in children: an observational study","volume":"4","author":"Samsonov","year":"2022","journal-title":"Kidney Med"},{"issue":"suppl 124","key":"10.1016\/j.semnephrol.2023.151435_bib0113","first-page":"195","article-title":"Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis","volume":"38","author":"Fenoglio","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0114","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.40339","article-title":"Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Sch\u00f6nlein)","volume":"70","author":"Maritati","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102490","article-title":"Rituximab treatment for IgA vasculitis: a systematic review","volume":"19","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0116","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0117","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1053\/j.ajkd.2015.08.004","article-title":"AJKD atlas of renal pathology: glomerulonephritis with dominant C3","volume":"66","author":"Lusco","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0118","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0119","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","article-title":"High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151435_bib0120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2215\/CJN.16801221","article-title":"Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis","volume":"17","author":"Lomax-Browne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0121","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0122","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/13816810.2015.1101777","article-title":"Retinal disease in the C3 glomerulopathies and the risk of impaired vision","volume":"37","author":"Savige","year":"2016","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.semnephrol.2023.151435_bib0123","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","article-title":"Nephritic factors: an overview of classification, diagnostic tools and clinical associations","volume":"10","author":"Corvillo","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0124","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151435_bib0127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151435_bib0128","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2215\/CJN.00320121","article-title":"C3 glomerulopathy and related disorders in children: etiology-phenotype correlation and outcomes","volume":"16","author":"Wong","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0129","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00467-020-04799-7","article-title":"Predictors of poor kidney outcome in children with C3 glomerulopathy","volume":"36","author":"P\u0131narba\u015f\u0131","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0130","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","article-title":"Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis","volume":"36","author":"Khandelwal","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151435_bib0131","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2215\/CJN.09541010","article-title":"Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees","volume":"6","author":"Athanasiou","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0132","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0133","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151435_bib0134","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years' experience at Mayo Clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151435_bib0135","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0136","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151435_bib0137","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151435_bib0138","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0139","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","article-title":"C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial","volume":"74","author":"Ruggenenti","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151435_bib0140","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00467-021-05088-7","article-title":"A clinical approach to children with C3 glomerulopathy","volume":"37","author":"Vivarelli","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151435_bib0141","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1681\/ASN.2019040433","article-title":"Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy","volume":"31","author":"Levine","year":"2020","journal-title":"J Am Soc Nephrol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:47:44Z","timestamp":1748357264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0270929523001456"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151435","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glomerular Diseases Across Lifespan: Key Differences in Diagnostic and Therapeutic Approaches","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151435"}}